文献速递前列腺癌

新诊断转移性前列腺癌年发病率上升:基于监测、流行病学和最终结果数据库的当代分析

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
PubMed 文献 · Eur Urol Oncol · 2018-05-15

基于美国监测、流行病学和最终结果数据库2004至2014年12 939例新诊断转移性前列腺癌患者,分析年发病率及初诊时疾病特征变化。结果显示年龄标化发病率从1.9例/10万升至2.4例/10万,cT1、Gleason评分8-10及M1a比例升高,初诊年龄从71岁降至68岁,PSA水平稳定。作者认为可能与PSA筛查减少导致的诊断延迟有关。

要点

  • 2004至2014年新诊断转移性前列腺癌年龄标化发病率从1.9例/10万升至2.4例/10万。
  • cT1比例从23%升至37%,Gleason评分8-10比例从67%升至85%。
  • 初诊年龄从71岁降至68岁,PSA水平保持稳定。

核心结论

  • 过去十年新诊断转移性前列腺癌发病率增加25%,初诊年龄下降,可能提示与PSA筛查减少相关的诊断延迟。

研究设计与样本

  • 基于监测、流行病学和最终结果数据库(2004-2014年)识别12 939例新诊断转移性前列腺癌患者。
  • 使用LOWESS绘制年龄、PSA(<50、50-98和>98ng/ml)、临床T分期(T1、T2和T3-4)、活检Gleason评分(≤6、7和8-10)及M1a、M1b、M1c亚分期的年度趋势。
  • 采用多变量逻辑回归检验更当代诊断年份(2014年)对PSA、cT分期、Gleason评分和M亚分期分布的影响,多变量线性回归检验对患者年龄的影响。

主要发现

  • 2004至2014年,新诊断转移性前列腺癌年龄标化发病率从1.9例/10万升至2.4例/10万(比值比[OR] 1.30,95%置信区间[CI] 1.18-1.44;p<0.0001)。
  • cT1比例从23%升至37%(OR 1.85;p<0.0001),Gleason评分8-10比例从67%升至85%(OR 2.62;p<0.0001),M1a疾病比例从4.5%升至6.0%(OR 2.16;p=0.006)。
  • 初诊转移性前列腺癌时患者年龄从71岁降至68岁(系数-0.14;p<0.001)。
  • 诊断时PSA水平随时间保持稳定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 局限性在于缺乏转移性疾病分布的详细信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reported recommendations against prostate specific antigen (PSA) screening may have negatively affected the rates of newly diagnosed metastatic prostate cancer (mPCa). OBJECTIVES: To investigate the annual rate of newly diagnosed mPCa and changes in disease characteristic at presentation over time in a large North American patient cohort. DESIGN, SETTING, AND PARTICIPANTS: Within the Surveillance, Epidemiology and End Results database (2004-2014) we identified 12 939 patients newly diagnosed with mPCa. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We used LOWESS to plot the annual trends for age, PSA (<50, 50-98, and >98ng/ml), clinical T stage (T1, T2, and T3-4), biopsy Gleason score ([GS] ≤6, 7, and 8-10), and M1a, M1b, and M1c substages. Multivariable logistic regression was used to test the effect of more contemporary year of diagnosis (YOD; 2014) on PSA, cT stage, GS, and M substage distributions. Multivariable linear regression was used to test the effect of more contemporary YOD on patient age. RESULTS AND LIMITATIONS: Between 2004 and 2014, the age-adjusted incidence of newly diagnosed mPCa increased from 1.9 to 2.4 cases per 100 000 population (odds ratio [OR] 1.30, 95% confidence interval [CI] 1.18-1.44; p<0.0001). Rates of cT1 (from 23% to 37%; OR 1.85; p<0.0001), GS 8-10 (from 67% to 85%; OR 2.62; p<0.0001), and M1a disease (from 4.5% to 6.0%; OR 2.16; p=0.006) increased. Conversely, patient age at initial mPCa diagnosis decreased from 71 to 68 yr (coefficient -0.14; p<0.001). The PSA level at diagnosis remained stable over time. A limitation is the lack of detail on the distribution of metastatic disease. CONCLUSIONS: The rate of newly diagnosed mPCa increased by 25% over the past decade and the age at initial presentation decreased. These observations may be indicative of diagnostic delays related to less frequent PSA screening. PATIENT SUMMARY: The US Preventive Services Task Force recommendations against prostate cancer screening might have indirectly caused an increase in the rate of newly diagnosed metastatic prostate cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Bandini M, Mazzone E, Preisser F, et al. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. Eur Urol Oncol. 2018. PMID: 31100253. doi:10.1016/j.euo.2018.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。